Spots Global Cancer Trial Database for The Efficacy and Safety of IBI363 in Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Efficacy and Safety of IBI363 in Solid Tumors
Official Title: A Prospective, Multi-cohort Study on Efficacy and Safety of IBI363 for Advanced Solid Tumors
Study ID: NCT06081907
Conditions
Study Description
Brief Summary: The study is a prospective multi-cohort clinical study. The study is divided into two phases, Phase Ia and Phase Ib. In Phase Ia, a dose escalation portion was conducted using a 3+3 dose-escalation design, with a preference for enrolling subjects with advanced non-small cell lung cancer and melanoma. Phase Ib represents the cohort expansion phase, comprising seven cohorts.
Detailed Description: The study is a prospective multi-cohort clinical study. The study is divided into two phases, Phase Ia and Phase Ib. In Phase Ia, a dose escalation portion was conducted using a 3+3 dose-escalation design, with a preference for enrolling subjects with advanced non-small cell lung cancer and melanoma. Phase Ib represents the cohort expansion phase, comprising seven cohorts. All the research data were collected follow the SAP.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Yongchang Zhang, Changsha, Hunan, China
Contact Details
Name: Yongchang Zhang
Affiliation: Hunan Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Nong Yang
Affiliation: Hunan Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Xiang Chen
Affiliation: Xiangya Hospital of Central South University
Role: PRINCIPAL_INVESTIGATOR
Name: Hong Liu
Affiliation: Xiangya Hospital of Central South University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
